Bharat Biotech International Ltd
Show jobs for this employer
52 articles with Bharat Biotech International Ltd
-
The DSMB for Ocugen's Phase I/II trial of OCU400, a gene therapy in development for Retinitis Pigmentosa (RP), recommended the study proceed with enrolling more patients.
-
Some researchers are pointing to the need for an intranasal approach to vaccination in order to block the viral particles from gaining a foothold in the body at the point of entry – the nose.
-
Two companies in India have halted vaccine manufacturing, which could be a sign that the pandemic may be coming to an end. For that and more COVID-19 news, continue reading.
-
The death toll related to COVID-19 is more than 6 million, according to the Johns Hopkins COVID-19 dashboard, but it has long been suspected that the toll is significantly higher.
-
The FDA turned down Ocugen’s Emergency Use Authorization request for Covaxin in children 2 to 18, which the company is co-developing with India’s Bharat Biotech.
-
The Omicron surge appears to be waning in the U.S., but a subvariant of Omicron seems to be surging in other countries where the Omicron surge faded.
-
Clinical Catch-Up: January 10-14
1/17/2022
Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look. -
One hundred percent of test serum samples showed neutralization of the delta variant, and more than ninety percent of serum samples showed neutralization of the Omicron variant.
-
The U.S. averages more than 700,000 new COVID-19 cases per day. As of Saturday, there were 4.91M cases, more cases in seven days than in April, May, June, and July 2021 combined.
-
Low-income countries still struggle to get first jabs into arms. Researchers and pharma companies continue to push for low-cost vaccines and drugs worldwide.
-
Clinical Catch-Up: December 27-31
1/3/2022
Not surprisingly, the week between Christmas and New Year was quiet in terms of clinical trial news. However, there were some announcements. Here’s a look. -
Positive data from a Phase II/III trial of Bharat Biotech vaccine, Covaxin. Read more about the research and know about the efficiency of the vaccine.
-
Omicron has caused the U.S. to install travel bans against several South African countries while vaccine makers rush to test their vaccines against it. For that news and more, continue reading.
-
Merck and Ridgeback Biotherapeutics’ antiviral drug molnupiravir, which showed great promise against COVID-19 in clinical trials, received its first authorization.
-
Pennsylvania-based Ocugen has submitted an Investigational New Drug (IND) to the FDA to run a Phase III trial of India’s BBV152 (Covaxin), a vaccine against COVID-19.
-
A subtype of the Delta variant might be rising, although it’s not yet clear if it’s more transmissible or lethal than the original Delta variant. Read on for that and more COVID-19 news.
-
Although there are many effective and safe COVID-19 vaccines around the world, the preferred vaccine is the Pfizer-BioNTech vaccine. For that and more stories, read on.
-
Clinical Catch-Up: September 6-10
9/13/2021
It was a very busy week for clinical trial announcements, although there were only three that were COVID-19-related. Here’s a look. -
This marks the second vaccine against the novel coronavirus developed by the India-based company and brings a significant milestone for intranasal formulations.
-
By administering a vaccine directly into the nasal cavity, the mucus membranes of the nose and throat would provide better protection than the intramuscular alone.